SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001404644-24-000026
Filing Date
2024-04-02
Accepted
2024-04-02 15:43:33
Documents
13
Period of Report
2024-04-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ngne-20240401.htm   iXBRL 8-K 29732
  Complete submission text file 0001404644-24-000026.txt   157692

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20240401.xsd EX-101.SCH 1907
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20240401_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20240401_pre.xml EX-101.PRE 13050
16 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20240401_htm.xml XML 2802
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 980542593 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 24813900
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)